NASDAQ:ABUS

Arbutus Biopharma Stock Forecast, Price & News

$3.25
-0.01 (-0.31 %)
(As of 06/18/2021 12:00 AM ET)
Add
Compare
Today's Range
$3.16
$3.29
50-Day Range
$2.50
$3.51
52-Week Range
$1.71
$9.02
Volume1.31 million shs
Average Volume2.02 million shs
Market Capitalization$313.26 million
P/E RatioN/A
Dividend YieldN/A
Beta2.93
30 days | 90 days | 365 days | Advanced Chart
Receive ABUS News and Ratings via Email

Sign-up to receive the latest news and ratings for Arbutus Biopharma and its competitors with MarketBeat's FREE daily newsletter.


Arbutus Biopharma logo

About Arbutus Biopharma

Arbutus Biopharma Corporation, a biopharmaceutical company, engages in the discovery, development, and commercialization of a cure for patients suffering from chronic Hepatitis B virus (HBV) infection in the United States. Its HBV product pipeline consists of AB-729, a proprietary subcutaneously-delivered RNA interference product candidate, which in an ongoing Phase Ia/Ib clinical trial targeted to hepatocytes that inhibits viral replication and reduces various HBV antigens using novel covalently conjugated GalNAc delivery technology; and AB-836, an oral capsid inhibitor that suppresses HBV DNA replication. The company's research and development programs include HBV RNA destabilizers, an orally active agent to destabilize HBV RNA, which leads to RNA degradation and to reduction in HBV proteins; oral PD-L1 inhibitor to enable reawakening patients' HBV-specific immune response; and small molecule antiviral medicines to treat coronaviruses, including COVID-19. It has strategic alliance, licensing, and research collaboration agreements with Marqibo; Gritstone Oncology, Inc.; and Alnylam Pharmaceuticals, Inc. and Acuitas Therapeutics, Inc. The company was formerly known as Tekmira Pharmaceuticals Corporation and changed its name to Arbutus Biopharma Corporation in July 2015. Arbutus Biopharma Corporation is headquartered in Warminster, Pennsylvania.

Headlines

See More Headlines

Industry, Sector and Symbol

Sales & Book Value

Profitability

Debt

Price-To-Earnings

Miscellaneous


MarketRank

Overall MarketRank

1.35 out of 5 stars

Medical Sector

803rd out of 2,100 stocks

Pharmaceutical Preparations Industry

396th out of 830 stocks

Analyst Opinion: 3.3Community Rank: 2.8Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.6 5 -4 -3 -2 -1 -
speech bubbles
speech bubbles











Arbutus Biopharma (NASDAQ:ABUS) Frequently Asked Questions

Is Arbutus Biopharma a buy right now?

6 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Arbutus Biopharma in the last twelve months. There are currently 2 hold ratings and 4 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" Arbutus Biopharma stock.
View analyst ratings for Arbutus Biopharma
or view top-rated stocks.

What stocks does MarketBeat like better than Arbutus Biopharma?

Wall Street analysts have given Arbutus Biopharma a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Arbutus Biopharma wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

When is Arbutus Biopharma's next earnings date?

Arbutus Biopharma is scheduled to release its next quarterly earnings announcement on Friday, August 6th 2021.
View our earnings forecast for Arbutus Biopharma
.

How were Arbutus Biopharma's earnings last quarter?

Arbutus Biopharma Co. (NASDAQ:ABUS) released its earnings results on Tuesday, May, 4th. The biopharmaceutical company reported ($0.21) EPS for the quarter, topping analysts' consensus estimates of ($0.23) by $0.02. The biopharmaceutical company earned $2.11 million during the quarter, compared to the consensus estimate of $3.87 million.
View Arbutus Biopharma's earnings history
.

How has Arbutus Biopharma's stock been impacted by COVID-19 (Coronavirus)?

Arbutus Biopharma's stock was trading at $2.58 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization. Since then, ABUS stock has increased by 26.0% and is now trading at $3.25.
View which stocks have been most impacted by COVID-19
.

What price target have analysts set for ABUS?

6 equities research analysts have issued 12 month target prices for Arbutus Biopharma's shares. Their forecasts range from $5.00 to $10.00. On average, they anticipate Arbutus Biopharma's stock price to reach $7.00 in the next twelve months. This suggests a possible upside of 115.4% from the stock's current price.
View analysts' price targets for Arbutus Biopharma
or view top-rated stocks among Wall Street analysts.

Who are Arbutus Biopharma's key executives?

Arbutus Biopharma's management team includes the following people:
  • Mr. William H. Collier, Pres, CEO & Director (Age 60, Pay $972.32k)
  • Dr. Michael J. Sofia, Chief Scientific Officer (Age 63, Pay $637.75k)
  • Mr. Michael J. McElhaugh, Chief Bus. Officer (Age 47, Pay $603.42k)
  • Mr. David C. Hastings, CFO & Chief Accounting Officer (Age 60)
  • Pam Murphy, Investor Relations Consultant
  • Dr. Elizabeth Howard, Exec. VP, Gen. Counsel, Chief Compliance Officer & Sec. (Age 67)
  • Dr. Gaston Picchio Ph.D., Chief Devel. Officer (Age 58)
  • Mr. R. Hector Mackay-Dunn B.A., L.L.B., Q.C., J.D., Q.C, Sec. (Age 70)

What is Mark J. Murray's approval rating as Arbutus Biopharma's CEO?

6 employees have rated Arbutus Biopharma CEO Mark J. Murray on Glassdoor.com. Mark J. Murray has an approval rating of 22% among Arbutus Biopharma's employees. This puts Mark J. Murray in the bottom 10% of approval ratings compared to other CEOs of publicly-traded companies.

Who are some of Arbutus Biopharma's key competitors?

What other stocks do shareholders of Arbutus Biopharma own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Arbutus Biopharma investors own include Ballard Power Systems (BLDP), Chiasma (CHMA), Bausch Health Companies (BHC), Heat Biologics (HTBX), Sorrento Therapeutics (SRNE), GW Pharmaceuticals (GWPH), Inovio Pharmaceuticals (INO), Alibaba Group (BABA), TherapeuticsMD (TXMD) and Novavax (NVAX).

What is Arbutus Biopharma's stock symbol?

Arbutus Biopharma trades on the NASDAQ under the ticker symbol "ABUS."

Who are Arbutus Biopharma's major shareholders?

Arbutus Biopharma's stock is owned by many different institutional and retail investors. Top institutional investors include BlackRock Inc. (2.18%), Morgan Stanley (1.17%), Point72 Asset Management L.P. (1.08%), Renaissance Technologies LLC (1.04%), Geode Capital Management LLC (0.55%) and Millennium Management LLC (0.54%).
View institutional ownership trends for Arbutus Biopharma
.

Which institutional investors are selling Arbutus Biopharma stock?

ABUS stock was sold by a variety of institutional investors in the last quarter, including Ameriprise Financial Inc., Morgan Stanley, Bank of Montreal Can, Citigroup Inc., Goldman Sachs Group Inc., and Bank of New York Mellon Corp.
View insider buying and selling activity for Arbutus Biopharma
or view top insider-selling stocks.

Which institutional investors are buying Arbutus Biopharma stock?

ABUS stock was bought by a variety of institutional investors in the last quarter, including Point72 Asset Management L.P., Renaissance Technologies LLC, Millennium Management LLC, GSA Capital Partners LLP, BlackRock Inc., Cubist Systematic Strategies LLC, Geode Capital Management LLC, and Barclays PLC.
View insider buying and selling activity for Arbutus Biopharma
or or view top insider-buying stocks.

How do I buy shares of Arbutus Biopharma?

Shares of ABUS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Arbutus Biopharma's stock price today?

One share of ABUS stock can currently be purchased for approximately $3.25.

How much money does Arbutus Biopharma make?

Arbutus Biopharma has a market capitalization of $313.26 million and generates $6.91 million in revenue each year. The biopharmaceutical company earns $-63,740,000.00 in net income (profit) each year or ($1.00) on an earnings per share basis.

How many employees does Arbutus Biopharma have?

Arbutus Biopharma employs 76 workers across the globe.

What is Arbutus Biopharma's official website?

The official website for Arbutus Biopharma is www.arbutusbio.com.

Where are Arbutus Biopharma's headquarters?

Arbutus Biopharma is headquartered at 701 VETERANS CIRCLE, WARMINSTER PA, 18974.

How can I contact Arbutus Biopharma?

Arbutus Biopharma's mailing address is 701 VETERANS CIRCLE, WARMINSTER PA, 18974. The biopharmaceutical company can be reached via phone at 267-469-0914 or via email at [email protected]


This page was last updated on 6/19/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.